Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625876 | 1.00 | MEN1 (0.56) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL1625885 | 1.00 | MEN1 (0.56) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL8815966 | 0.92 | KMT2A (0.57) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL28906676 | 0.85 | TSHR (0.50) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL19342847 | 0.85 | KMT2A (0.50) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL1023274 | 0.84 | TSHR (0.57) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL5715396 | 0.84 | LOXL2 (0.55) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL27579834 | 0.83 | KMT2A (0.52) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL10621456 | 0.81 | LMNA (0.50) | MEN1KMT2ATSHRLOXL2ALDH1A1 | |
| SCHEMBL10695276 | 0.81 | TSHR (0.59) | MEN1KMT2ATSHRLOXL2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217917-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | THE UNIVERSITY OF STAVANGER (NO) | 2024-07-04 | — | — | US | disclosed |
| EP-2934594-B1 | CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES . | ALMIRALL SA (ES) | 2019-09-04 | — | — | EP | disclosed |
| US-9518050-B2 | Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity | ALMIRALL, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2015-11-19 | — | — | US | disclosed |
| EP-2934594-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | Almirall, S.A. (ES) | 2015-10-28 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-101967146-B | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC | 2015-04-08 | — | — | CN | disclosed |
| WO-2014095920-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | ALMIRALL, S.A. (ES) | 2014-06-26 | — | — | WO | disclosed |
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| CN-1282243-A | Pharmaceutical composition containing anilide derivative for antagonizing CCR5 | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
| EP-0647133-A4 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. | AFFYMAX TECH NV (AN) | 1997-10-29 | — | — | EP | disclosed |
| US-5607691-A | IONTOPHORESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-03-04 | — | — | US | disclosed |
| EP-0647133-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-04-12 | — | — | EP | disclosed |
| WO-1993025197-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-12-23 | — | — | WO | disclosed |
| CN-86102923-A | The method for preparing antibiotic derivatives | — | 1986-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329535-A1 | NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY | CHRM3, CHRM2, ADRB2 | MEN1 3031/4885KMT2A 984/4885TSHR 225/4885 |
| US-20240217917-A1 | PHOTOLYTICALLY DEGRADABLE COMPOUNDS AND METHODS | DDT, DDC, CTRC | MEN1 2480/4885KMT2A 2563/4885TSHR 2972/4885 |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | MEN1 3912/4885KMT2A 2917/4885TSHR 4596/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | MEN1 4826/4885KMT2A 3764/4885TSHR 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.